PMID- 25404148
OWN - NLM
STAT- MEDLINE
DCOM- 20141229
LR  - 20220330
IS  - 0893-9675 (Print)
IS  - 0893-9675 (Linking)
VI  - 19
IP  - 5
DP  - 2014
TI  - Glioblastoma heterogeneity and cancer cell plasticity.
PG  - 327-36
AB  - Glioblastoma (GBM) is the most common and malignant type of primary brain tumor. 
      It represents one of the deadliest human cancers, with an average survival at 
      diagnosis of about 1 year. This poor prognosis is due to therapeutic resistance 
      and tumor recurrence after surgical removal. One of the most important hallmarks 
      of GBM is tumor heterogeneity. Intertumor heterogeneity is mostly characterized 
      by distinct genetic alterations that occur in individual tumors originating in 
      the same organ and allows the classification of these tumors into different 
      molecular subtypes. Intratumor heterogeneity-the diversity within individual 
      tumors-has become the focus of research interest in the past few years, and tumor 
      cell plasticity as a new source of cancer stem cells has added another level of 
      complexity to this phenomenon. This review describes the molecular heterogeneity 
      of GBMs at the transcriptome level and the expression profile-based 
      classification of histopathologically indistinguishable tumors into different 
      subtypes. In addition, the role of dedifferentiation of tumor cells into a stem 
      cell-like state is discussed as a source of cellular heterogeneity within tumors, 
      highlighting tumor cell plasticity as an important driver of GBM heterogeneity. 
      Understanding tumor heterogeneity will help design better therapies against GBM 
      and avoid tumor recurrence.
FAU - Friedmann-Morvinski, Dinorah
AU  - Friedmann-Morvinski D
AD  - Laboratory of Genetics, The Salk Institute for Biological Studies, La Jolla, 
      California; Department of Biochemistry and Molecular Biology, The George S. Wise 
      Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Crit Rev Oncog
JT  - Critical reviews in oncogenesis
JID - 8914610
SB  - IM
MH  - Animals
MH  - Brain Neoplasms/*pathology
MH  - Glioblastoma/*pathology
MH  - Humans
MH  - Mice
MH  - Neoplastic Stem Cells/pathology
EDAT- 2014/11/19 06:00
MHDA- 2014/12/30 06:00
CRDT- 2014/11/19 06:00
PHST- 2014/11/19 06:00 [entrez]
PHST- 2014/11/19 06:00 [pubmed]
PHST- 2014/12/30 06:00 [medline]
AID - 1f524cb22209e814,3490845833249f99 [pii]
AID - 10.1615/critrevoncog.2014011777 [doi]
PST - ppublish
SO  - Crit Rev Oncog. 2014;19(5):327-36. doi: 10.1615/critrevoncog.2014011777.